Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 248

1.

Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats.

Nirbhavane P, Sharma G, Singh B, Khuller GK, Goni VG, Patil AB, Katare OP.

AAPS PharmSciTech. 2018 Oct;19(7):3187-3198. doi: 10.1208/s12249-018-1148-3. Epub 2018 Aug 24.

PMID:
30143947
2.

Lipid Nanocarrier-Mediated Drug Delivery System to Enhance the Oral Bioavailability of Rifabutin.

Nirbhavane P, Vemuri N, Kumar N, Khuller GK.

AAPS PharmSciTech. 2017 Apr;18(3):829-837. doi: 10.1208/s12249-016-0559-2. Epub 2016 Jun 27.

PMID:
27350276
3.

Comparative Evaluation of Several Gene Targets for Designing a Multiplex-PCR for an Early Diagnosis of Extrapulmonary Tuberculosis.

Raj A, Singh N, Gupta KB, Chaudhary D, Yadav A, Chaudhary A, Agarwal K, Varma-Basil M, Prasad R, Khuller GK, Mehta PK.

Yonsei Med J. 2016 Jan;57(1):88-96. doi: 10.3349/ymj.2016.57.1.88.

4.

Serodiagnostic potential of immuno-PCR using a cocktail of mycobacterial antigen 85B, ESAT-6 and cord factor in tuberculosis patients.

Singh N, Sreenivas V, Sheoran A, Sharma S, Gupta KB, Khuller GK, Mehta PK.

J Microbiol Methods. 2016 Jan;120:56-64. doi: 10.1016/j.mimet.2015.11.016. Epub 2015 Nov 25.

PMID:
26625715
5.

Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.

Gupta UD, Vemuri N, Gupta P, Kumar V, Tanushree P, Khuller GK.

Indian J Med Res. 2015 Sep;142(3):323-9. doi: 10.4103/0971-5916.166599.

6.

Diagnosis of pulmonary and extrapulmonary tuberculosis based on detection of mycobacterial antigen 85B by immuno-PCR.

Singh N, Sreenivas V, Gupta KB, Chaudhary A, Mittal A, Varma-Basil M, Prasad R, Gakhar SK, Khuller GK, Mehta PK.

Diagn Microbiol Infect Dis. 2015 Dec;83(4):359-64. doi: 10.1016/j.diagmicrobio.2015.08.015. Epub 2015 Aug 31.

PMID:
26422085
7.

Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study.

Arora A, Shafiq N, Jain S, Khuller GK, Sharma S, Malhotra S.

PLoS One. 2015 Jun 5;10(6):e0128208. doi: 10.1371/journal.pone.0128208. eCollection 2015.

8.

Detection of potential microbial antigens by immuno-PCR (PCR-amplified immunoassay).

Mehta PK, Raj A, Singh NP, Khuller GK.

J Med Microbiol. 2014 May;63(Pt 5):627-41. doi: 10.1099/jmm.0.070318-0. Epub 2014 Feb 25. Review.

PMID:
24568881
9.

Poly(lactide-co-glycolide)-rifampicin nanoparticles efficiently clear Mycobacterium bovis BCG infection in macrophages and remain membrane-bound in phago-lysosomes.

Kalluru R, Fenaroli F, Westmoreland D, Ulanova L, Maleki A, Roos N, Paulsen Madsen M, Koster G, Egge-Jacobsen W, Wilson S, Roberg-Larsen H, Khuller GK, Singh A, Nyström B, Griffiths G.

J Cell Sci. 2013 Jul 15;126(Pt 14):3043-54. doi: 10.1242/jcs.121814. Epub 2013 May 17.

10.

Diagnosis of extrapulmonary tuberculosis by PCR.

Mehta PK, Raj A, Singh N, Khuller GK.

FEMS Immunol Med Microbiol. 2012 Oct;66(1):20-36. doi: 10.1111/j.1574-695X.2012.00987.x. Epub 2012 Jun 29. Review.

11.

Optimization, in vitro-in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation.

Kumar G, Sharma S, Shafiq N, Khuller GK, Malhotra S.

J Pharm Sci. 2012 Jun;101(6):2165-76. doi: 10.1002/jps.23087. Epub 2012 Mar 5.

PMID:
22392918
12.

Development of an ultrasensitive polymerase chain reaction-amplified immunoassay based on mycobacterial RD antigens: implications for the serodiagnosis of tuberculosis.

Mehta PK, Kalra M, Khuller GK, Behera D, Verma I.

Diagn Microbiol Infect Dis. 2012 Feb;72(2):166-74. doi: 10.1016/j.diagmicrobio.2011.10.010.

PMID:
22248737
13.

In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis.

Kumar G, Malhotra S, Shafiq N, Pandhi P, Khuller GK, Sharma S.

J Microencapsul. 2011;28(8):717-28. doi: 10.3109/02652048.2011.615948. Epub 2011 Oct 10.

PMID:
21985449
14.

Evaluation of Aro-Tal-AST Complex Protein as a Marker for Differential Diagnosis of Mycobacterium Avium Infection.

Gupta K, Verma I, Khuller GK, Mahajan R.

J Glob Infect Dis. 2011 Jul;3(3):259-64. doi: 10.4103/0974-777X.83532.

15.

Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy.

Sheikh JA, Khuller GK, Verma I.

J Immune Based Ther Vaccines. 2011 Jun 26;9:4. doi: 10.1186/1476-8518-9-4.

16.

Nonspecificity of 35 kDa protein: a proposed marker for the differential diagnosis of M. avium infection in the Indian population.

Gupta K, Mahajan R, Khuller GK, Verma I.

Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):718-22. doi: 10.4103/0377-4929.72053.

17.

Nanobead-based interventions for the treatment and prevention of tuberculosis.

Griffiths G, Nyström B, Sable SB, Khuller GK.

Nat Rev Microbiol. 2010 Nov;8(11):827-34. doi: 10.1038/nrmicro2437. Epub 2010 Oct 12. Review.

PMID:
20938454
18.

Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis.

Kumar G, Sharma S, Shafiq N, Pandhi P, Khuller GK, Malhotra S.

Drug Deliv. 2011 Jan;18(1):65-73. doi: 10.3109/10717544.2010.509367. Epub 2010 Aug 24.

PMID:
20735202
19.

Evaluation of Mycobacterium tuberculosis specific RD antigens for delayed type hypersensitivity responses in guinea pig.

Kalra M, Khuller GK, Sheikh JA, Verma I.

Indian J Exp Biol. 2010 Feb;48(2):117-23.

PMID:
20455320
20.

Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.

Sharma A, Khuller GK, Kanwar AJ, Sharma S.

J Infect. 2010 Jun;60(6):498-501. doi: 10.1016/j.jinf.2010.03.009. Epub 2010 Mar 25. No abstract available.

PMID:
20346970
21.

Utility of a combination of RD1 and RD2 antigens as a diagnostic marker for tuberculosis.

Kalra M, Khuller GK, Grover A, Behera D, Wanchu A, Verma I.

Diagn Microbiol Infect Dis. 2010 Feb;66(2):153-61. doi: 10.1016/j.diagmicrobio.2009.09.005. Epub 2009 Oct 15.

PMID:
19833469
22.

Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.

Sharma A, Khuller GK, Sharma S.

Expert Opin Ther Targets. 2009 Jul;13(7):753-65. doi: 10.1517/14728220903005590. Review.

PMID:
19530983
23.

In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.

Sharma A, Sharma S, Khuller GK, Kanwar AJ.

Int J Antimicrob Agents. 2009 Sep;34(3):226-30. doi: 10.1016/j.ijantimicag.2009.04.005. Epub 2009 Jun 7.

PMID:
19505802
24.

Identification of Mycobacterium avium KatG protein (MAV_2753) as a possible serodiagnostic marker for MAC disease.

Gupta K, Khuller GK, Wanchu A, Laal S, Latawa R, Verma I.

J Infect. 2009 Feb;58(2):170-2. doi: 10.1016/j.jinf.2008.12.002. Epub 2009 Jan 26. No abstract available.

PMID:
19176248
25.

Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection.

Giri PK, Verma I, Khuller GK.

Immunotherapy. 2009 Jan;1(1):31-7. doi: 10.2217/1750743X.1.1.31.

PMID:
20635971
26.

Alginate-based sustained release drug delivery systems for tuberculosis.

Ahmad Z, Khuller GK.

Expert Opin Drug Deliv. 2008 Dec;5(12):1323-34. doi: 10.1517/17425240802600662 . Review.

PMID:
19040395
27.

Is intranasal vaccination a feasible solution for tuberculosis?

Giri PK, Khuller GK.

Expert Rev Vaccines. 2008 Nov;7(9):1341-56. doi: 10.1586/14760584.7.9.1341. Review.

PMID:
18980538
28.

Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.

Ahmad Z, Pandey R, Sharma S, Khuller GK.

Indian J Chest Dis Allied Sci. 2006 Jul-Sep;48(3):171-6.

PMID:
18610673
29.

Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.

Ahmad Z, Pandey R, Sharma S, Khuller GK.

Int J Antimicrob Agents. 2008 Feb;31(2):142-6. Epub 2007 Dec 26.

PMID:
18155883
30.

Identification and purification of CREB like protein in Candida albicans.

Singh A, Dhillon NK, Sharma S, Khuller GK.

Mol Cell Biochem. 2008 Jan;308(1-2):237-45. Epub 2007 Nov 16.

PMID:
18008148
31.
32.

Supplementation with RD antigens enhances the protective efficacy of BCG in tuberculous mice.

Kalra M, Grover A, Mehta N, Singh J, Kaur J, Sable SB, Behera D, Sharma P, Verma I, Khuller GK.

Clin Immunol. 2007 Nov;125(2):173-83. Epub 2007 Sep 4.

PMID:
17766185
33.
34.

cAMP regulates vegetative growth and cell cycle in Candida albicans.

Singh A, Sharma S, Khuller GK.

Mol Cell Biochem. 2007 Oct;304(1-2):331-41. Epub 2007 Jun 8.

PMID:
17557192
35.

Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.

Sable SB, Kalra M, Verma I, Khuller GK.

Clin Immunol. 2007 Mar;122(3):239-51. Epub 2007 Jan 5. Review.

PMID:
17208519
36.

Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.

Ahmad Z, Sharma S, Khuller GK, Singh P, Faujdar J, Katoch VM.

Int J Antimicrob Agents. 2006 Dec;28(6):543-4. Epub 2006 Nov 13.

PMID:
17101262
37.

Lung and blood mononuclear cell responses of tuberculosis patients to mycobacterial proteins.

Sable SB, Goyal D, Verma I, Behera D, Khuller GK.

Eur Respir J. 2007 Feb;29(2):337-46. Epub 2006 Nov 1.

38.

A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens.

Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK.

Microbes Infect. 2006 Aug;8(9-10):2390-9. Epub 2006 Jul 18.

PMID:
16962360
39.

Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.

Ahmad Z, Sharma S, Khuller GK.

FEMS Microbiol Lett. 2006 Aug;261(2):181-6.

41.
42.

Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs.

Pandey R, Sharma S, Khuller GK.

Drug Deliv. 2006 Jul-Aug;13(4):287-94.

PMID:
16766470
43.

Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model.

Grover A, Ahmed MF, Verma I, Sharma P, Khuller GK.

Protein Expr Purif. 2006 Aug;48(2):274-80. Epub 2006 Mar 30.

PMID:
16716602
44.

Nanotechnology based drug delivery system(s) for the management of tuberculosis.

Pandey R, Khuller GK.

Indian J Exp Biol. 2006 May;44(5):357-66. Review.

PMID:
16708887
45.

The potential of azole antifungals against latent/persistent tuberculosis.

Ahmad Z, Sharma S, Khuller GK.

FEMS Microbiol Lett. 2006 May;258(2):200-3.

46.

Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.

Ahmad Z, Pandey R, Sharma S, Khuller GK.

Int J Antimicrob Agents. 2006 May;27(5):409-16. Epub 2006 Apr 19.

PMID:
16624533
47.

Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model.

Pandey R, Khuller GK.

J Antimicrob Chemother. 2006 Jun;57(6):1146-52. Epub 2006 Apr 5.

PMID:
16597631
48.
49.

Polymer based drug delivery systems for mycobacterial infections.

Pandey R, Khuller GK.

Curr Drug Deliv. 2004 Jul;1(3):195-201. Review.

PMID:
16305383
50.

Oral solid lipid nanoparticle-based antitubercular chemotherapy.

Pandey R, Sharma S, Khuller GK.

Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):415-20. Epub 2005 Oct 26.

PMID:
16256437

Supplemental Content

Loading ...
Support Center